KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Restructuring: 2018-2019

Historic Cash from Restructuring for Arbutus Biopharma (ABUS) over the last 2 years, with Dec 2019 value amounting to -$66,000.

  • Arbutus Biopharma's Cash from Restructuring fell 111.76% to -$66,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$983,000, marking a year-over-year decrease of 159.04%. This contributed to the annual value of -$983,000 for FY2019, which is 173.85% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Restructuring of -$66,000 as of Q4 2019, which was up 52.17% from -$138,000 recorded in Q3 2019.
  • In the past 5 years, Arbutus Biopharma's Cash from Restructuring ranged from a high of $1.0 million in Q1 2018 and a low of -$640,000 during Q2 2019.
  • In the last 2 years, Arbutus Biopharma's Cash from Restructuring had a median value of -$102,000 in 2019 and averaged $85,250.
  • Examining YoY changes over the last 5 years, Arbutus Biopharma's Cash from Restructuring showed a top increase of 56.88% in 2019 and a maximum decrease of 262.03% in 2019.
  • Over the past 2 years, Arbutus Biopharma's Cash from Restructuring (Quarterly) stood at $561,000 in 2018, then crashed by 111.76% to -$66,000 in 2019.
  • Its last three reported values are -$66,000 in Q4 2019, -$138,000 for Q3 2019, and -$640,000 during Q2 2019.